What’s Next In Biologics? Biosimilar Expert Predicts Big Fall Changes

With so many biosimilars in the U.S. pipeline, the federal government has had its hands full in recent months managing legislation and expectations from patient groups, health organizations, pharmaceutical companies and advocates. While debates rage on and in-fighting has severed several previously harmonious relationships, the fall is expected to bring some big changes to the biosimilar world. To better understand what September and beyond hold for the space, I sat down with Dr. Sarfaraz Niazi, a biosimilar expert and advisor on several biologics-based bills introduced in the House and Senate.